Tuesday, October 19, 2021

Prevnar 13 lags amid COVID-19 vaccine rollouts, but Pfizer sees a way to boost the franchise


Pfizer’s pneumococcal vaccine Prevnar 13 has long been the world’s bestselling vaccine, but that’s set to change in 2021 thanks to the company’s own COVID-19 shot. As the COVID-19 vaccine rollout hits its stride, Pfizer’s key Prevnar franchise is slumping.

During the first three months of the year, Pfizer’s Prevnar 13 sales fell 11% to $1.28 billion. In the U.S., which is well underway with its COVID-19 vaccination push, the decline was more dramatic: Prevnar sales fell 20% stateside, thanks to a 57% decline in adults and a 6% drop in children.

Why the declines?

COVID-19 continued to put a damper on regular doctor visits for adults. Plus, many people started receiving COVID-19 vaccines, limiting the other shots they could get. The Centers for Disease Control and Prevention recommends people don’t get other vaccines within two weeks of their COVID-19 shots.

Meanwhile, Pfizer blamed its lower sales in kids on pandemic disruptions, as well as lower year-over-year birth rates.

RELATED: Ready to square off with Pfizer in next-gen pneumococcal vaccines, a Merck exec says competition’s a good thing

But with COVID-19 boosters looking increasingly necessary, Pfizer has co-administration of vaccines in its sights. The company has a 20-valent pneumococcal conjugate vaccine in the hopper, 20vPnC, up for an FDA decision in June. The company says it plans to run a safety and immunogenicity study on the co-administration of that shot and a COVID-19 booster dose. 

Results from that study are expected in the third quarter, with the potential to sway the Advisory Committee on Immunization Practices’ guidance on the co-administration of Prevnar 13 and Pfizer-BioNTech’s pandemic shot, too, the company said. 

Pfizer isn’t the only drugmaker to see its bread-and-butter vaccine business slip during the pandemic. Facing similar holdups from the U.S. vaccination push, Merck reported that sales of its HPV shot Gardasil fell 16% to $917 million in the first quarter of 2021. The company’s polysaccharide pneumococcal vaccine Pneumovax 23 slumped 33% to $171 million.

RELATED: Merck pulls close to Pfizer in next-gen pneumococcal vaccine race as FDA fast-tracks 15-strain vaccine

GlaxoSmithKline, for its part, blamed COVID-19 vaccine rollouts for a “significant disruption” to its vaccine business in Q1. Sales of the company’s shingles vaccine Shingrix plummeted nearly 50% versus the same quarter last year. Still, GSK’s pharma president, Luke Miels, called the sales slump a “timing issue,” noting that the company expects Shingles revenues to rebound later this year.

Meanwhile, Pfizer didn’t talk much about its long-running Prevnar vaccine franchise on its first quarter earnings call Tuesday as analysts homed in on COVID-19. 

The vaccine generated about $5.9 billion in 2020 according to Pfizer’s annual report. In the U.S., Prevnar reeled in some $2.9 billion for the full year. 



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...